» Latest Treatments

Isolaz: A New Painless Laser Treatment for Acne

Peter Hinson - Editor — Mon, 31 Aug 2009 11:31:43 +0000

Many people suffer from serious acne issues and though they’ve tried treatment after treatment, they still are unable to find relief from their blemishes. Acne can damage more than just the skin, it is hard on the self confidence as well.

Now there’s hope for those who’ve tried medications to no avail, the Isolaz treatment. Using gentle suction combined with laser therapy, the Isolaz treatment clears pores without pain and kills the acne causing bacteria. According to the manufacturer, Aesthera, it is the only painless laser acne treatment as well as the only system that truly deep cleans the pores from the inside out. In addition, it has received approval from the FDA for the treatment of both comedonal and postular acne.

The vacuum treatment is able to pull the pores closer to the light source so that the patient receives a truly targeted treatment. Patients see an immediate improvement with pimples visibly reduced within just one to two days. Also, the amount of oil produced by the skin is reduced after just one treatment.

The cost and number of treatments needed varies greatly depending on the area being treated, the kind of acne, and the severity of the acne issues. Isolaz has been found to be effective on people who’ve tried other treatments with no luck and can be used on all skin types.

Before treatment, the skin is hydrated. The provider then places the treatment tip on the skin and the patient will feel a warm sensation as it is being used. It is fast with only about 20 minutes needed for treatment. 100% of patients report no pain and liken the sensation to a warm massage.

Isolaz has been featured on “The Doctors” and “The Today Show,” as well as in several popular magazines around the world including “New Beauty” and “O: The Oprah Magazine

Source: www.americanhealthandbeauty.com

Rosacea Treatment Rosadyn Pilot Study Results Better Than Expected

Peter Hinson - Editor — Sat, 29 Aug 2009 18:41:18 +0000

New York, NY, August 29, 2009 –(PR.com)-- Vascular Health Specialists (VHS), a firm dedicated to leveraging the latest dermatologic research to develop cutting-edge skin care products, is pleased to announce the pilot study results of their Rosadyn nutraceutical product, which targets flushing, redness and inflammation of facial skin.
Thirty-five (35) individuals who had been previously diagnosed with rosacea were selected and monitored through the first 4 weeks of an ongoing pilot study to evaluate the effect of Rosadyn on inflammatory skin symptoms. Participants took the daily-recommended dosage of Rosadyn and reported their progress via weekly online surveys conducted by the firm.
Findings
Participants reported improvement in a range of symptoms, most notably in the areas of flushing, redness and skin sensitivity. Highlights of the results by symptom are detailed below:
Flushing and Redness:
– 94% of participants reported a reduction in facial flushing with an average reduction level of 46.0%.
– 89% of participants reported a reduction in facial redness with an average reduction level of 44.5%.
– 66% of participants reported a reduction in broken blood vessels with an average reduction level of 39.5%.
– 60% of participants reported a reduction in facial swelling with an average reduction level of 38.0%.
Skin Sensitivity:
– 91% of participants reported a reduction in overall skin discomfort with an average reduction level of 51.3%.
– 89% of participants reported a reduction in hyper-sensitive skin with an average reduction level of 50.9%.
– 89% of participants reported a reduction in burning and stinging sensations with an average reduction level of 50.6%.
Papules and Pustules:
– 63% of participants reported a reduction in inflammatory papules (small red bumps) with an average reduction level of 38.6%.
– 31% of participants reported a reduction in inflammatory pustules (red bumps with pus) with an average reduction level of 29.5%.
Other Symptom Improvements:
– 91% of participants reported a reduction in anxiety during rosacea flares and triggers with an average reduction level of 48.0%.
– 51% of participants reported a reduction in global ocular rosacea symptoms with an average reduction level of 43.3%.
Side Effects
Participants were also asked to report any side effects associated with Rosadyn usage. The weekly survey included both a text box for participants to report any side effects in their own words, as well as a multiple choice question which asked testers to rate the level of any adverse reactions on a scale of 1-10, ranging from None, Mild, Moderate, to Severe.
In total, 89% of respondents reported no side effects at all. Of the remaining 11%, all reported effects were in the Mild range. There were no reports of any side effects at the Moderate or Severe level.
Overall Satisfaction
To gauge overall satisfaction with Rosadyn usage, participants were asked to rate the overall status of their rosacea symptoms after Rosadyn compared to pre-test levels. In total, 91% of testers reported an improvement in the overall status of their rosacea with an average improvement level of 49%. Moreover, in response to a question of whether participants would recommend the product to fellow rosacea sufferers, 75% indicated they would.
According to Dr. Geoffrey Nase, Ph.D, VHS’s founder and developer of Rosadyn, the results surpassed the expectations of the team, “While we certainly had faith that the pharmaceutical grade ingredients selected would target key symptoms, we were surprised at the speed and breadth of the reported improvements. We were particularly encouraged by the overall reduction in flushing, as this is an inherently unresponsive symptom. The pathophysiology behind such conditions involves months or years of chronic inflammation and cellular damage that usually takes time to reverse and normalize, so these findings exceeded our expectations. That said, the importance of continued supplementation must be emphasized as inflammatory skin symptoms often require several skin renewal cycles in order to maintain a healthy skin state.”
Dr. Bitter, Sr., a partner in VHS and collaborator on Rosadyn development, commented on the results, “It was particularly rewarding to see the heartfelt testimonials and gratitude from participants who have struggled with the condition for years with only negligible improvement at best.”
Deep Skin Inflammation and Skin Renewal
The Rosadyn Pilot study will continue to monitor the progress of testers at the two, three and six month periods. Early results indicate steady and continued improvement past the 4-week mark by most testers, highlighting the fact that the desired results may require at least 3 months (2 full skin-renewal cycles). More comprehensive testing of the affects on Rosadyn’s affect on rosacea symptoms are currently under development by Vascular Health Specialists. Additional Pilot Study details will be published shortly on the Rosadyn.com website.
About Vascular Health Specialists:
Vascular Health Specialists (VHS) is a firm dedicated to leveraging the latest dermatologic research to develop cutting edge products for rosacea and other skin conditions. Comprised of a team of professionals with backgrounds in medicine, research, business and skin care product development, VHS works closely with leading laboratories and nutraceutical manufacturers to remain at the forefront of novel skin treatments.
For more information, please visit the company website at: http://www.rosadyn.com

Laser Combined With Topical Therapy Cures Acne Completely

Peter Hinson - Editor — Wed, 01 Jul 2009 21:06:00 +0000

Dermatologist Macrene Alexiades-Armenakas, MD, PhD, FAAD, assistant clinical professor of dermatology at Yale University School of Medicine in New Haven, Conn., demonstrated how photodynamic therapy combined with a long-pulse, pulsed-dye laser and topical 5-aminolevulinic acid provides long-lasting clearance of acne lesions.
“Laser technology has made great inroads in the treatment of acne, which until recently has been treated almost exclusively, and with varying degrees of success, with topical, systemic and hormonal medications,” said Alexiades-Armenakas.
She added: “Now, we have solid evidence-based medicine supporting the effectiveness of certain laser therapies as a long-term solution for treating active acne. The key is to distinguish the benefits and limitations of these available technologies and select the most effective treatments for each acne patient.”
In a preliminary study, Alexiades-Armenakas examined whether a combination of photodynamic therapy (PDT) with a photosensitizer known as topical 5-aminolevulinic acid (ALA) and activated by long-pulse, pulsed dye laser could safely and effectively clear mild to severe cases of acne.
PDT works by using laser or light energy, in this case a pulsed dye laser was used, to activate the ALA, which is a solution that penetrates into the oil glands and is applied to the skin one hour prior to treatment.